The American pharmaceutical manufacturer Eli Lilly exceeded market expectations.
In the company's report, it reports an adjusted result per share of 3.92 dollars. This can be compared to the analysts' forecast of 2.11 dollars.
Revenue increased to 11.30 billion dollars, an increase of 36 percent compared to the same period last year. Analysts had previously estimated revenue of 9.98 billion dollars.
The company is simultaneously announcing that it has raised its forecast for the full year 2024 to revenues of between 45.4-46.6 billion dollars, compared to previously 42.4-43.6 billion dollars.
Just like its competitor, the Danish weight loss giant Novo Nordisk, Eli Lilly has had great success with its diabetes medications that can also be used for treating obesity.
